Half-Year 2022 Financial and Clinical Trials Update

HY 2022: Group Core cost of sales (COS) Increase due to PP&E reversal in 2021, volume growth and change in the Pharma/Diagnostics sales mix Roche 839 165 9,322 CHFM 8,203 184 8,387 -69 COS as % of group sales 26.7% 27.3% Pharma Division's proportion of Group sales declines from 71% to 69% 28.8% COS HY 2021 Impairments of PP&E Normalized reversal COS HY 2021 10% volume increase Pharma/ Diagnostics sales mix Other movements COS HY 2022 HY 2021 All at CER=Constant Exchange Rates; COS-Cost of Sales; PP&E = Property, plant and equipment 57 57

View entire presentation